Publications database

This report presents the data and findings of the risk assessment on the new psychoactive substance, 3,4-dichloro-N-{[1-(dimethylamino)cyclohexyl]methyl}benzamide (AH-7921), that was conducted by the Scientific Committee of the EMCDDA. Concerns over this synthetic...

This paper offers a comparison of the drug strategies and plans adopted over the last five years by six intergovernmental organisations engaging 148 countries in four continents. It informs decision-makers, professionals and...

The report presents a review of tools for monitoring illicit drug use in prison population in Europe. The objective of the report is to describe the existing tools used at national level...

In this issue: Alarming rise in fatal overdoses in Estonia | Estimating public expenditure on drug-law offenders in prisons | EMCDDA embarks on 2014 work programme | EMCDDA steps up cooperation with...

This study estimates how much 22 European countries spent on drug-law offenders in prisons during the last decade. Based on this, an estimate for public expenditure on drug-law offenders at the European...

This is a first common questionnaire on drug use among prisoners at European level. The questionnaire is the results of two years of work in the field of drugs and prison, which...

During adolescence, some young people may experiment with both licit and illicit substances (alcohol, tobacco, cannabis and other drugs). This can have an impact on their behaviour, their relationships with others and...

The 2014 Work programme continues to implement the commitments set out in the EMCDDA’s 2013–15 strategy and work programme. It builds on the achievements made in 2013 where measures were put in...

The EMCDDA receives stable funding under Commission budget line B3-441 of the general budget of the European Union. Each year, a preliminary draft budget is presented by the Centre's Director to the...

The EMCDDA–Europol Joint Report on new psychoactive substance 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine, commonly known by the abbreviation ‘25I-NBOMe’, submitted in December 2013 to the Council of the EU, the European Commission and the EMA. After...